Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation

Ibrutinib has significantly improved the outcome of patients with relapsed chronic lymphocytic leukemia (CLL). Recent reports attribute ibrutinib resistance to acquired mutations in Bruton agammaglobulinemia tyrosine kinase (BTK), the target of ibrutinib, as well as the immediate downstream effector...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Blood
Prif Awduron: Liu, Ta-Ming, Woyach, Jennifer A., Zhong, Yiming, Lozanski, Arletta, Lozanski, Gerard, Dong, Shuai, Strattan, Ethan, Lehman, Amy, Zhang, Xiaoli, Jones, Jeffrey A., Flynn, Joseph, Andritsos, Leslie A., Maddocks, Kami, Jaglowski, Samantha M., Blum, Kristie A., Byrd, John C., Dubovsky, Jason A., Johnson, Amy J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2015
Pynciau:
Lymphoid Neoplasia
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4492196/
https://ncbi.nlm.nih.gov/pubmed/25972157
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-02-626846
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg